Educational Risk Minimisation Materials to help reduce the risk associated with using this medicine.
This reminder card contains important safety information that patients need to be aware of before and during treatment with denosumab (XGEVA) injections for cancer-related conditions, A side effect called osteonecrosis of the jaw (ONJ, bone damage in the jaw) has been reported commonly (may affect up to 1 in 10 people) in patients receiving XGEVA injections for cancer-related conditions. ONJ can also occur after stopping treatment. It is important to try to prevent ONJ developing as it may be a painful condition that can be difficult to treat. In order to reduce the risk of developing ONJ, there are some precautions patients should take. To request a copy of the patient card, please contact Amgen Medical Information on +44 (0) 1223 436441